November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery.

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk,

November 9, 2021 — Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure the severity of artery blockages can lead to significantly improved outcomes after percutaneous coronary intervention (PCI), according to a new study done in collaboration with Mount Sinai faculty.

November 20, 2021 – Philips announced it signed an agreement to acquire Cardiologs, a France-based medical technology company focused on cardiac diagnostics using artificial intelligence (AI) and cloud technology. Cardiologs will further strengthen Philips’ cardiac monitoring and diagnostics offering with innovative software technology, electrocardiogram (ECG) analysis and reporting services. 

November 9, 2021 — Caption Health and Ultromics, developers of artificial intelligence (AI) to improve cardiac ultrasound diagnostics, announced a strategic partnership to accelerate cardiovascular disease detection and treatment for more patients in more accessible care settings. Together, the companies will jointly offer the Caption AI software platform alongside Ultromics’ EchoGo deep ultrasound analytics. 

November 9, 2021 — The COVID-19 (SARS-CoV-2) virus does not infect blood vessels, despite the high risk of blood clots to COVID-19 patients, researchers recently found at University of Queensland in Australia.

November 9 2021 — A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes data from of peripheral vascular interventions guided by intravascular ultrasound (IVUS) showed a  32% reduction in major adverse limb events, such as amputations, during lower extremity arterial intervention. 

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage (LAA) transcatheter occluder with the new generation Boston Scientific Watchman FLX transcatheter occluder.

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system demonstrated favorable patient outcomes were sustained at six months. Results from the TRISCEND study, treating patients with tricuspid regurgitation, were presented during the late-breaking clinical science session at the 2021 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting of the Cardiovascular Research Foundation.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now